EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial

Morris K Rutakingirwa iD, Caleb P Skipper iD, Biyue Dai iD, Abduljewad Wele, Suzan Namombwe, Timothy Mugabi iD, Jane Frances Ndyetukira, Alisat Sadiq, Mable Kabahubya, Lenard Chemusto, Cynthia Ahimbisibwe, Shifa Nabbale und 13 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf432 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Morris K Rutakingirwa und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: Meningitis, Cryptococcal, Flucytosine, Antifungal Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Neurologic Disorders and Stroke, NIAID NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cryptococcosis is a leading cause of death among people with human immunodeficeincy virus (HIV). Guidelines recommend combination therapy with amphotericin B and flucytosine, but standard flucytosine dosing of 100 mg/kg/day is associated with hematologic toxicity. The FLOOR trial investigated whether lower flucytosine dosing maintained therapeutic efficacy and reduced toxicity.

Methods

This phase 2, single-arm, open-label trial enrolled 48 adults with HIV and confirmed cryptococcal meningitis at 2 hospitals in Uganda. Participants received 10 days of flucytosine at 60 mg/kg/day in 3 divided doses, combined with liposomal amphotericin B (10 mg/kg, single dose) and fluconazole 1200 mg/day for 14 days, followed by standard consolidation therapy. The primary endpoint was the early fungicidal activity (EFA), which measures the rate of Cryptococcus clearance in the cerebrospinal fluid (CSF) in the first 14 days of therapy. Secondary endpoints included CSF sterility at 2 weeks, 18-week survival, and adverse events.

Results

The EFA of reduced dose flucytosine was 0.28 log10 colony forming units (CFU)/mL/day (95% CI, .20 to .35), which was lower than historical controls in Uganda receiving flucytosine at 100 mg/kg/day of 0.41 log10 CFU/mL/day (P = .019). At 18 weeks, the estimated survival probability was 77% (95% CI, 66% to 90%). The incidence of rehospitalization (25%) and culture-positive relapse (6.3%) were higher than expected. Grades 3 and 4 hematologic toxicity was similar (10% leukopenia; 21% anemia) to historical incidence.

Conclusions

Reduced flucytosine dose of 60 mg/kg/day for 10 days demonstrated inferior efficacy in CSF fungal clearance. These findings support further investigation of dose optimization strategies. Trial Registration ClinicalTrials.gov: NCT06414512.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningitis, CryptococcalFlucytosineAntifungal AgentsHumansAdultMaleFemaleUgandaAmphotericin BMiddle AgedTreatment OutcomeFluconazoleHIV InfectionsDrug Therapy, CombinationYoung AdultAIDS-Related Opportunistic Infections

Stichwörter der Autor:innen

HIVcryptococcosisearly fungicidal activityflucytosinemeningitis

Substanzen

FlucytosineAntifungal AgentsAmphotericin Bliposomal amphotericin BFluconazole

Autor:innen und Institutionen

  • Department of Research, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Internal Medicine, Kiruddu National Referral Hospital, Kampala, Uganda.
  • Department of Internal Medicine, Soroti University, Soroti, Uganda.
  • Department of Internal Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
  • Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom.

ORCID-Profile: Morris K Rutakingirwa, Caleb P Skipper, Biyue Dai, Timothy Mugabi, Rhona C B Muyise, Enock Kagimu, Jonathan Mulungi, Samuel Jjunju, Melanie R Nicol, Katharine E Stott, Richard Kwizera, David B Meya, David R Boulware, Thomas C McHale

Förderung

  • National Institute of Neurologic Disorders and Stroke
  • NIAID NIH HHS
  • NINDS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • FIC NIH HHS

Zitieren

APA

Rutakingirwa, M. K., Skipper, C. P., Dai, B., Wele, A., Namombwe, S., Mugabi, T., Ndyetukira, J. F., Sadiq, A., Kabahubya, M., Chemusto, L., Ahimbisibwe, C., Nabbale, S., Kandole, T. K., Muyise, R. C. B., Kagimu, E., Luggya, T., Mulungi, J., Jjunju, S., Nicol, M. R., …, & FLOOR trial team (2026). Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf432

Vancouver

Rutakingirwa MK, Skipper CP, Dai B, Wele A, Namombwe S, Mugabi T, et al. Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf432

BibTeX
@article{Rutakingirwa2026,
  author = {Rutakingirwa, Morris K and Skipper, Caleb P and Dai, Biyue and Wele, Abduljewad and Namombwe, Suzan and Mugabi, Timothy and Ndyetukira, Jane Frances and Sadiq, Alisat and Kabahubya, Mable and Chemusto, Lenard and Ahimbisibwe, Cynthia and Nabbale, Shifa and Kandole, Tadeo Kiiza and Muyise, Rhona C B and Kagimu, Enock and Luggya, Tonny and Mulungi, Jonathan and Jjunju, Samuel and Nicol, Melanie R and Stott, Katharine E and Kwizera, Richard and Meya, David B and Boulware, David R and McHale, Thomas C and FLOOR trial team, FLOOR trial team},
  title = {Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf432}
}
Kostenlos starten →